AbbVie Stock Drops 41.93% in Trading Volume, Ranks 136th Despite Promising Migraine Treatment Data

AbbVie (ABBV) closed at $150.00 on June 18, 2025, with a trading volume of $513 million, down 41.93% from the previous day, ranking 136th in the day's stock market. The stock has been on a downward trend for four consecutive days, with a total decline of 3.61% over the past four days.

AbbVie recently announced new data from its Phase 3 TEMPLE study, demonstrating significant progress in migraine treatment. The study showed that atogepant, a novel migraine treatment, achieved superior efficacy compared to topiramate, a commonly used migraine medication. Over a 24-week double-blind treatment period, the discontinuation rate due to adverse events was significantly lower with atogepant (12.1%) compared to topiramate (29.6%). Additionally, 64.1% of patients treated with atogepant achieved at least a 50% reduction in monthly migraine days, compared to 39.3% for topiramate.

These positive results from the TEMPLE study are expected to bolster investor confidence in AbbVie's migraine treatment pipeline. The superior efficacy and lower discontinuation rate of atogepant compared to topiramate suggest that atogepant could become a leading treatment option for migraine patients. This development is likely to have a positive impact on AbbVie's stock price in the long term, as the company continues to invest in innovative treatments for neurological disorders.